Cardiomyocyte death in patients with end-stage heart failure before and after support with a left ventricular assist device: Low incidence of apoptosis despite ubiquitous mediators

Journal of Heart and Lung Transplantation

Volumn 22, Issue 9, 2003, Pages 1028-1036

  De Jonge, Nicolaas ^a   Van Wichen, Dick F ^a   Van Kuik, Joyce ^a   Kirkels, Hans ^a   Lahpor, Jaap R ^a   Gmelig Meyling, Frits H J ^a   Van Den Tweel, Jan G ^a   De Weger, Roel A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CASPASE 3; DEOXYURIDINE TRIPHOSPHATE DERIVATIVE; DNA NUCLEOTIDYLEXOTRANSFERASE; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; APOPTOSIS; ARTICLE; CELL DEATH; CELL NUCLEUS; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMPLANTATION; INCIDENCE; MALE; NICK END LABELING; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 0041736398     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)01160-9     Document Type: Article

References (35)

1. Mann D.L. Mechanisms and models in heart failure, a combinatorial approach. Circulation. 100:1999;999-1008.
2. Sabbah H.N. Apoptotic cell death in heart failure. Cardiovas Res. 45:2000;704-712.
3. Kang P.M., Izumo S. Apoptosis and heart failure. A critical review of the literature. Circ Res. 86:2000;1107-1113.
4. Olivetti G., Abbi R., Quaini F., et al. Apoptosis in the failing human heart. N Engl J Med. 336:1997;1131-1141.
5. Narula J., Haider N., Virmani R., et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 335:1996;1182-1189.
6. Saraste A., Pulkki K., Kallajoki M., et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Invest. 29:1999;380-386.
7. Bartling B., Milting H., Schuman H., et al. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation. 100:(supplII):1999;II-216-223.
8. Francis G.S., Anwar F., Bank A.J., et al. Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart observations made after implantation of left ventricular assist device . J Cardiac Failure. 5:1999;308-315.
9. De Jonge N., Kirkels H., Lahpor J.R., et al. Exercise performance in patients with end-stage heart failure after implantation of a left ventricular assist device and after heart transplantation an outlook for permanent assisting? J Am Coll Cardiol. 37:2001;1794-1799.
10. Wijsman J.H., Jonker R.R., Keijzer R., et al. A new method to detect apoptosis in paraffin sections in situ end labeling of fragmented DNA . J Histochem Cytochem. 41:1993;7-12.
11. Van Hoffen E., Van Wichen D.F., Leemans J.C., et al. T cell apoptosis in human heart allografts. Association with lack of co-stimulation? Am J Pathol. 153:1998;1813-1824.
12. Ohno M., Takemura G., Ohno A., et al. Apoptotic myocytes in infarcted area in rabbit hearts may be oncotic myocytes with DNA fragmentation. Analysis by immunogold electron microscopy combined with in situ nick end-labeling. Circulation. 98:1998;1422-1430.
13. Kanoh M., Takemura G., Misao J., et al. Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy. Not apoptosis but DNA repair. Circulation. 99:1999;2757-2764.
14. Kockx M.M., Muhring J., Knaapen M.W.M., et al. RNA synthesis and splicing interferes with DNA in situ end labeling techniques used to detect apoptosis. Am J Pathol. 152:1998;885-888.
15. De Boer R.A., Van Veldhuisen D.J., Van der Wijk J., et al. Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure. J Cardiac Failure. 6:2000;330-337.
16. Birks E.J., Latif N., Owen V., et al. Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation. 104:(supplI):2001;I-233-240.
17. Cook S.A., Poole-Wilson P.A. Cardiac myocyte apoptosis. Eur Heart J. 20:1999;1619-1629.
18. Oliver J.F., de la Rubia G., Rolli V., et al. Importance of poly (ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem. 273:1998;33533-33539.
19. Lazebnik Y.A., Kaufman S.H., Desnoyers S., et al. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 371:1994;346-347.
20. Rössig L., Haendeler J., Mallat Z., et al. Congestive heart failure induces endothelial cell apoptosis protective role of carvedilol . J Am Coll Cardiol. 36:2000;2081-2089.
21. Scarabelli T., Stephanou A., Rayment N., et al. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. Circulation. 104:2001;253-256.
22. Kubota T., Miyagishima M., Frye C.S., et al. Overexpression of tumor necrosis factor-α activates both anti- and pro-apoptotic pathways in the myocardium. J Moll Cell Cardiol. 33:2001;1331-1334.
23. Black R.A., Rauch C.T., Kozlosky C.J., et al. A metalloproteinase disintegrin that releases tumor necrosis factor-α from cells. Nature. 385:1997;729-733.
24. Torre-Amione G., Kapadia S., Lee J., et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 92:1995;1487-1493.
25. Krown K.A., Page M.T., Nguyen C., et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 98:1996;2854-2865.
26. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
27. Satoh M., Nakamura M., Saitoh H., et al. Tumor necrosis factor-α-converting enzyme and tumor necrosis factor-α in human dilated cardiomyopathy. Circulation. 99:1999;3260-3265.
28. Torre-Amione G., Stetson S.J., Youker K.A., et al. Decreased expression of tumor necrosis factor-α in failing human myocardium after mechanical circulatory support. A potential mechanism for cardiac recovery. Circulation. 100:1999;1189-1193.
29. Suda T., Takahashi T., Golstein P., et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
30. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
31. Jeremias I., Kupatt C., Martin-Villalba A., et al. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation. 102:2000;915-920.
32. Wollert K.C., Heineke J., Westerman J., et al. The cardiac Fas (Apo-1/CD95) receptor/Fas ligand system. Relation to diastolic wall stress in volume-overload hypertrophy in vivo and activation of the transcription factor AP-1 in cardiac myocytes. Circulation. 101:2000;1172-1178.
33. Irmler M., Thome M., Hahne M., et al. Inhibition of death receptor signals by cellular FLIP. Nature. 388:1997;190-195.
34. Houser S.R., Lakatta E.G. Function of the cardiac myocyte in the conundrum of end-stage, dilated human heart failure. Circulation. 99:1999;600-604.
35. De Jonge N., Van Wichen D.F., Schipper M.E.I., et al. Left ventricular assist device in end-stage heart failure persistence of structural myocyte damage after unloading. An immunohistochemical analysis of the contractile myofilaments . J Am Coll Cardiol. 39:2002;963-969.